AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8203876 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 32
Study 3299568 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambroxol (10 mg/kg, i.v. twice daily for 7 days)
Number of subjects: 28
Study 3299568 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 29464846 — intervention group
Group type: EXPERIMENTAL
Intervention: DCB with ELCA
Number of subjects: 168
Study 29464846 — intervention group
Group type: COMPARATOR
Intervention: Stent with ELCA
Number of subjects: 168
Study 29464846 — intervention group
Group type: COMPARATOR
Intervention: Stent without ELCA
Number of subjects: 168
Study 27470605 — intervention group
Group type: EXPERIMENTAL
Intervention: Age 10-17 years
Number of subjects: 318
Study 27470605 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight (>1 standard deviation)
Number of subjects: 318
Study 27470605 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 318
Study 27470605 — intervention group
Group type: EXPERIMENTAL
Intervention: Event-free survival
Number of subjects: 318
Study 27470605 — intervention group
Group type: COMPARATOR
Intervention: Children aged 10-17 years
Number of subjects: 318
Study 27470605 — intervention group
Group type: COMPARATOR
Intervention: Infants
Number of subjects: 318
Study 27470605 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight children aged 10-17 years
Number of subjects: 318
Study 25711667 — intervention group
Group type: EXPERIMENTAL
Intervention: VO2max
Number of subjects: 52
Study 25711667 — intervention group
Group type: EXPERIMENTAL
Intervention: HRR
Number of subjects: 52
Study 25711667 — intervention group
Group type: EXPERIMENTAL
Intervention: HRmax
Number of subjects: 52
Study 23291937 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually tailored educational web pages addressing specific vaccine concerns
Number of subjects: 77
Study 23291937 — intervention group
Group type: COMPARATOR
Intervention: Untailored educational web pages containing general information
Number of subjects: 77
Study 23291937 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually tailored educational web pages
Number of subjects: 77
Study 23291937 — intervention group
Group type: COMPARATOR
Intervention: Untailored educational web pages
Number of subjects: 77
Study 20701112 — intervention group
Group type: EXPERIMENTAL
Intervention: Technologies adopted for provision in outpatient care
Number of subjects: 36
Study 20701112 — intervention group
Group type: COMPARATOR
Intervention: Technologies excluded from provision
Number of subjects: 36
Study 20701112 — intervention group
Group type: COMPARATOR
Intervention: Technologies suspended for assessment
Number of subjects: 36
Study 20701112 — intervention group
Group type: COMPARATOR
Intervention: Negative decisions based on evidence
Number of subjects: 36
Study 20701112 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive decisions lacking RCT evidence
Number of subjects: 36
Study 17997313 — intervention group
Group type: EXPERIMENTAL
Intervention: Barbiturate coma
Number of subjects: 12
Study 16173858 — intervention group
Group type: EXPERIMENTAL
Intervention: Responsive parenting intervention
Number of subjects: 264
Study 16173858 — intervention group
Group type: COMPARATOR
Intervention: Developmental information (Control)
Number of subjects: 264
Study 14557454 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH antagonist infusion
Number of subjects: 11
Study 14557454 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (control)
Number of subjects: 11
Study 10805184 — intervention group
Group type: EXPERIMENTAL
Intervention: albendazole therapy
Number of subjects: 500
Study 10805184 — intervention group
Group type: COMPARATOR
Intervention: untreated children
Number of subjects: 500
Study 8927671 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg fluoxetine daily
Number of subjects: 0
Study 8927671 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg fluoxetine weekly
Number of subjects: 0
Study 8927671 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1830488 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy (CO2 laser)
Number of subjects: 12
Study 1830488 — intervention group
Group type: COMPARATOR
Intervention: Classic cholecystectomy
Number of subjects: 12
Study 7104182 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin retard 75 mg twice daily
Number of subjects: 15
Study 7104182 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin capsules 50 mg three times daily
Number of subjects: 15
Study 7104182 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin 100 mg suppository at night with 50 mg by mouth each morning
Number of subjects: 15
Study 7104182 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin retard therapy
Number of subjects: 15
Study 7104182 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional oral therapy
Number of subjects: 15
Study 7104182 — intervention group
Group type: COMPARATOR
Intervention: All treatments
Number of subjects: 15
Study 31056252 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-based immunosuppression (EVR) with reduced cyclosporin A
Number of subjects: 24
Study 31056252 — intervention group
Group type: COMPARATOR
Intervention: Standard immunosuppression (STD) with standard cyclosporin A and mycophenolate mofetil
Number of subjects: 24
Study 31056252 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-based immunosuppression (EVR) with MFI cut-off level set to 6000
Number of subjects: 24
Study 31056252 — intervention group
Group type: COMPARATOR
Intervention: Standard immunosuppression (STD) with MFI cut-off level set to 6000
Number of subjects: 24
Study 27822663 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping Cat program (CBT-based intervention)
Number of subjects: 141
Study 27822663 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 141
Study 27180314 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibogaine 20 mg
Number of subjects: 21
Study 27180314 — intervention group
Group type: COMPARATOR
Intervention: Paroxetine or placebo (control)
Number of subjects: 21
Study 24401051 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper-airway stimulation
Number of subjects: 126
Study 22429766 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent regular aspirin use
Number of subjects: 4771
Study 22429766 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent regular ibuprofen use
Number of subjects: 4771
Study 22429766 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency of NSAID use
Number of subjects: 4771
Study 22429766 — intervention group
Group type: EXPERIMENTAL
Intervention: Any recent NSAID use
Number of subjects: 4771
Study 19769500 — intervention group
Group type: EXPERIMENTAL
Intervention: Autograft bone harvested from the iliac crest
Number of subjects: 0
Study 19769500 — intervention group
Group type: EXPERIMENTAL
Intervention: Allograft bone from either cadaveric iliac crest or fibula
Number of subjects: 0
Study 19769500 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanium cages and rectangular fusion devices
Number of subjects: 0
Study 19769500 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyetheretherketone cages
Number of subjects: 0
Study 19769500 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human bone morphogenic protein-2
Number of subjects: 0
Study 19769500 — intervention group
Group type: COMPARATOR
Intervention: Standard approach
Number of subjects: 0
Study 17126403 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorzolamide treatment
Number of subjects: 854
Study 17126403 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 854
Study 15896581 — intervention group
Group type: EXPERIMENTAL
Intervention: PCEA with 0.1% bupivacaine (Group 2)
Number of subjects: 30
Study 15896581 — intervention group
Group type: COMPARATOR
Intervention: PCEA without 0.1% bupivacaine (Group 1)
Number of subjects: 30
Study 15669935 — intervention group
Group type: EXPERIMENTAL
Intervention: Storytelling and conversations (Group B)
Number of subjects: 6
Study 15669935 — intervention group
Group type: COMPARATOR
Intervention: Dance, rhythm, and songs (Group A)
Number of subjects: 6
Study 10546604 — intervention group
Group type: EXPERIMENTAL
Intervention: Vastus splitting approach
Number of subjects: 51
Study 10546604 — intervention group
Group type: COMPARATOR
Intervention: Median parapatellar approach
Number of subjects: 51
Study 10546604 — intervention group
Group type: EXPERIMENTAL
Intervention: Both approaches
Number of subjects: 51
Study 9076841 — intervention group
Group type: EXPERIMENTAL
Intervention: Policosanol 10 mg day-1
Number of subjects: 37
Study 9076841 — intervention group
Group type: EXPERIMENTAL
Intervention: Policosanol 20 mg day-1
Number of subjects: 37
Study 9076841 — intervention group
Group type: EXPERIMENTAL
Intervention: Policosanol 40 mg day-1
Number of subjects: 37
Study 9076841 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 1859490 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) 7.5 mg weekly, increased based on clinical improvement
Number of subjects: 64
Study 1859490 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine (AZA) 100 mg daily, increased based on clinical improvement
Number of subjects: 64
Study 6356900 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol
Number of subjects: 91
Study 6356900 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 91
Study 6356900 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 91
Study 31705307 — intervention group
Group type: EXPERIMENTAL
Intervention: casein phosphopeptide‐amorphous calcium phosphate (CPP‐ACP) slurry
Number of subjects: 36
Study 31705307 — intervention group
Group type: EXPERIMENTAL
Intervention: PAA‐ACP@aMSN slurry
Number of subjects: 36
Study 31705307 — intervention group
Group type: COMPARATOR
Intervention: artificial saliva solution (negative control)
Number of subjects: 36
Study 30689016 — intervention group
Group type: EXPERIMENTAL
Intervention: Equivocal participants
Number of subjects: 65
Study 29352829 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-micronutrient powder (daily dose for 3 months)
Number of subjects: 722
Study 29352829 — intervention group
Group type: COMPARATOR
Intervention: No supplement (control group)
Number of subjects: 722
Study 27148807 — intervention group
Group type: EXPERIMENTAL
Intervention: SAPT with PLGM activated
Number of subjects: 36
Study 27148807 — intervention group
Group type: COMPARATOR
Intervention: SAPT alone
Number of subjects: 36
Study 24673045 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxibustion
Number of subjects: 160
Study 24673045 — intervention group
Group type: COMPARATOR
Intervention: Far-infrared therapy
Number of subjects: 160
Study 22287748 — intervention group
Group type: EXPERIMENTAL
Intervention: Nerve-sparing radical hysterectomy (NSRH)
Number of subjects: 56
Study 22287748 — intervention group
Group type: COMPARATOR
Intervention: Classical radical hysterectomy (RH)
Number of subjects: 56
Study 20185426 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium
Number of subjects: 810
Study 17983507 — intervention group
Group type: COMPARATOR
Intervention: Group O (Oxytocin): 20 U oxytocin injected into the uterine plus 20 U oxytocin intravascularly, 152 women
Number of subjects: 457
Study 17983507 — intervention group
Group type: EXPERIMENTAL
Intervention: Group O + H (Oxytocin + Hemabat): 20 U oxytocin and 250 microg hemabat injected into the uterine, 192 women
Number of subjects: 457
Study 17983507 — intervention group
Group type: EXPERIMENTAL
Intervention: Group H (Hemabat): 250 microg hemabat injected into the uterine, 125 women
Number of subjects: 457
Study 16257846 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemodialysis patients
Number of subjects: 11
Study 12161488 — intervention group
Group type: EXPERIMENTAL
Intervention: One etonogestrel implant
Number of subjects: 28
Study 12161488 — intervention group
Group type: EXPERIMENTAL
Intervention: Two etonogestrel implants
Number of subjects: 28
Study 12161488 — intervention group
Group type: COMPARATOR
Intervention: Control (baseline testosterone treatment)
Number of subjects: 28
Study 10198397 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF, 300 microgram sc)
Number of subjects: 0
Study 10198397 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7762524 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal acetate (12.5 mmol [1,2‐13C]sodium acetate)
Number of subjects: 5
Study 7762524 — intervention group
Group type: COMPARATOR
Intervention: Intravenous acetate (12.5 mmol [1,2‐13C]sodium acetate)
Number of subjects: 5
Study 7762524 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal acetate with propionate (6 mmol sodium propionate)
Number of subjects: 5
Study 30559087 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational tools (informative pamphlet, video, pictographic magnet)
Number of subjects: 269
Study 30559087 — intervention group
Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 269
Study 30559087 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational tools (pamphlet)
Number of subjects: 269
Study 30559087 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational tools (video)
Number of subjects: 269
Study 29370008 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional support initiated < 48 hours after injury
Number of subjects: 90
Study 29370008 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional support initiated 48 to < 72 hours after injury
Number of subjects: 90
Study 29370008 — intervention group
Group type: COMPARATOR
Intervention: No nutritional support over first 7 days
Number of subjects: 90
Study 28007026 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus cisplatin
Number of subjects: 0
Study 28007026 — intervention group
Group type: COMPARATOR
Intervention: Fluorouracil plus cisplatin
Number of subjects: 0
Study 24846822 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydromorphone ER (8-32 mg)
Number of subjects: 260
Study 24846822 — intervention group
Group type: COMPARATOR
Intervention: Oxycodone CR (10-40 mg)
Number of subjects: 260
Study 22385928 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental dentifrice (2% strontium chloride and 5% potassium nitrate)
Number of subjects: 81
Study 22385928 — intervention group
Group type: COMPARATOR
Intervention: Control dentifrice (no active ingredients)
Number of subjects: 81
Study 18931525 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone (HC) treatment for 10 days
Number of subjects: 46
Study 18931525 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 46
Study 18931525 — intervention group
Group type: EXPERIMENTAL
Intervention: Meta-analysis of hydrocortisone treatment
Number of subjects: 46
Study 17535145 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting training protocol (2-week duration, involving reaching tasks beyond arm's length)
Number of subjects: 12
Study 17535145 — intervention group
Group type: COMPARATOR
Intervention: Sham sitting training protocol (2-week duration, involving cognitive-manipulative tasks within arm's length)
Number of subjects: 12
Study 15074436 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month exercise training program (Group A: 16 patients)
Number of subjects: 26
Study 15074436 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group B: 10 patients)
Number of subjects: 26
Study 16134519 — intervention group
Group type: EXPERIMENTAL
Intervention: Transamin 1.0 g i.v.
Number of subjects: 400
Study 16134519 — intervention group
Group type: EXPERIMENTAL
Intervention: Transamin 0.5 g i.v.
Number of subjects: 400
Study 16134519 — intervention group
Group type: EXPERIMENTAL
Intervention: aminomethylbenzoic acid 0.5 g i.v.
Number of subjects: 400
Study 16134519 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 400
Study 9972173 — intervention group
Group type: EXPERIMENTAL
Intervention: Test toothpaste with zinc citrate trihydrate (ZCT) and triclosan in microgranules, delivered in a silica-based toothpaste containing 1450 ppm F as sodium fluoride, used for 13 weeks.
Number of subjects: 0
Study 9972173 — intervention group
Group type: COMPARATOR
Intervention: Negative control fluoridated toothpaste with no anti-calculus active, used for 13 weeks.
Number of subjects: 0
Study 8048854 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathoracic stomach after subtotal esophagectomy
Number of subjects: 21
Study 8048854 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 21
Study 8048854 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine blocker treatment for hemorrhagic ulcers
Number of subjects: 21
Study 3393383 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin 600 mg/kg/day (P)
Number of subjects: 17
Study 3393383 — intervention group
Group type: COMPARATOR
Intervention: Piperacillin 600 mg/kg/day plus tobramycin (PT)
Number of subjects: 17
Study 30439725 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise targeting segmental motion in mid‐thoracic spine for 2 months
Number of subjects: 20
Study 30439725 — intervention group
Group type: COMPARATOR
Intervention: Routine athletic training
Number of subjects: 20
Study 31758194 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA quartile Q4
Number of subjects: 405
Study 31758194 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA quartile Q2
Number of subjects: 405
Study 29511965 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-loss intervention (LEAN trial)
Number of subjects: 121
Study 29511965 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline BMI correlation (HOPE trial)
Number of subjects: 121
Study 29511965 — intervention group
Group type: EXPERIMENTAL
Intervention: Ingenuity Pathway Analysis (IPA)
Number of subjects: 121
Study 28317138 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychiatry specialty pharmacist intervention
Number of subjects: 25
Study 28317138 — intervention group
Group type: COMPARATOR
Intervention: Control group (hospital pharmacist intervention)
Number of subjects: 25
Study 25046536 — intervention group
Group type: EXPERIMENTAL
Intervention: CSE/CHX - Clearfil SE Bond + CHX
Number of subjects: 22
Study 25046536 — intervention group
Group type: EXPERIMENTAL
Intervention: CSE - Clearfil SE Bond
Number of subjects: 22
Study 25046536 — intervention group
Group type: EXPERIMENTAL
Intervention: ADS/CHX - AdheSE + CHX
Number of subjects: 22
Study 25046536 — intervention group
Group type: EXPERIMENTAL
Intervention: ADS - AdheSE
Number of subjects: 22
Study 25046536 — intervention group
Group type: COMPARATOR
Intervention: Control group (CSE and CSE/CHX)
Number of subjects: 22
Study 23079690 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate 35 mg delayed-release (DR) weekly (FB)
Number of subjects: 922
Study 23079690 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate 35 mg delayed-release (DR) weekly (BB)
Number of subjects: 922
Study 23079690 — intervention group
Group type: COMPARATOR
Intervention: Risedronate 5 mg immediate-release (IR) daily
Number of subjects: 922
Study 21570934 — intervention group
Group type: EXPERIMENTAL
Intervention: Biological causal model
Number of subjects: 461
Study 21570934 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological causal model
Number of subjects: 461
Study 21570934 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined causal model (biological and psychological)
Number of subjects: 461
Study 21570934 — intervention group
Group type: COMPARATOR
Intervention: No causal explanation
Number of subjects: 461
Study 18490891 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief group intervention combining stress management psycho-education and physical activity
Number of subjects: 87
Study 18490891 — intervention group
Group type: COMPARATOR
Intervention: Usual-care (control)
Number of subjects: 87
Study 16552618 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabis extract
Number of subjects: 630
Study 16552618 — intervention group
Group type: EXPERIMENTAL
Intervention: THC
Number of subjects: 630
Study 16552618 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 630
Study 14750508 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg)
Number of subjects: 32
Study 14750508 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 10790473 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative duration of middle ear effusion (MEE) in the first year of life
Number of subjects: 241
Study 10790473 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative duration of middle ear effusion (MEE) during antecedent periods
Number of subjects: 241
Study 10790473 — intervention group
Group type: COMPARATOR
Intervention: Socioeconomic status
Number of subjects: 241
Study 8804494 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 0
Study 8804494 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1321509 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin, 30 mg subcutaneously every 12 h for up to 14 days
Number of subjects: 131
Study 1321509 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 131
Study 6392163 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexabrix
Number of subjects: 50
Study 6392163 — intervention group
Group type: COMPARATOR
Intervention: Renografin-76
Number of subjects: 50
Study 31796805 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-day transcranial direct current stimulation (tDCS) targeting the somatosensory representation of the whole body (S1)
Number of subjects: 0
Study 31796805 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Source Separation algorithm for brain activity measurement
Number of subjects: 0
Study 28977360 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline 3MS score
Number of subjects: 5596
Study 28977360 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in 3MS as a time-varying covariate
Number of subjects: 5596
Study 27509020 — intervention group
Group type: EXPERIMENTAL
Intervention: Celgosivir (400 mg loading dose and 200 mg bid over 5 days)
Number of subjects: 50
Study 27509020 — intervention group
Group type: EXPERIMENTAL
Intervention: Celgosivir
Number of subjects: 50
Study 27509020 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 22551775 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS) applied to the right prefrontal cortex at 10 Hz, 100% of the observed motor threshold, for 2000 pulses per session, in a 10-session course over 2 weeks
Number of subjects: 9